Faculty, Staff and Student Publications

Language

English

Publication Date

3-10-2026

Journal

Blood Advances

DOI

10.1182/bloodadvances.2025017752

PMID

41201381

PMCID

PMC12964034

PubMedCentral® Posted Date

11-11-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Although previous studies have examined the drug development and clinical trial success rates in oncology, a comprehensive analysis of development success rate in lymphoma has not been performed. Therefore, we analyzed lymphoma trials initiated between 1 January 2000 and 31 December 2019, using the Trialtrove database and ClinicalTrials.gov. We identified phase 1, 2, and 3 trials that included patients with lymphoma and analyzed the transition rate of investigational agents across phases and their US Food and Drug Administration (FDA) approval rates to assess the efficiency and success of the clinical development process. A total of 1032 phase 1 trials and 510 phase 1/2 trials were conducted, with a total of 651 distinct agents being evaluated during the study period. There were 1027 phase 2, 20 phase 2/3, and 140 phase 3 trials conducted for lymphoma, with 200 agents proceeding from phase 1 to 2 and 46 agents proceeding from phase 2 to 3. The success rates of agents proceeding from phase 1 to 2 and phase 2 to 3 were 30.7% and 23.0%, respectively. A total of 40 agents reached FDA approval, with an overall approval rate of 6.1%. The average time from initiation of the first phase 1 trial to approval for lymphoma treatment was 7.9 years. Our study characterizes the clinical development landscape and timeline of novel therapies for lymphoma. Low approval rate from phase 1 trials in lymphoma suggests the need for improvement in trial design and in prediction of clinical response through preclinical studies to improve the likelihood of success.

Keywords

Humans, Lymphoma, Clinical Trials as Topic, Antineoplastic Agents, Drug Approval, United States, United States Food and Drug Administration, Drug Development

Published Open-Access

yes

Additional Files
BLOODA_ADV-2025-017752-ga1.jpg (522 kB)
Graphical Abstract
Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.